Pasithea Therapeutics Corp. (KTTA) Institutional Ownership

Ownership Summary

Pasithea Therapeutics Corp. (NASDAQ:KTTA) has 25 institutional investors with active 13F positions as of December 2025.

• These investors collectively held 173.2% of Pasithea Therapeutics's outstanding shares in December 2025, up from 7.8% in September 2025.
• They increased total shares held in KTTA by 2530.32% quarter over quarter, and investors in Pasithea Therapeutics increased 212.5% from a year ago.
• Activity in KTTA broke down as 18 buyers, 4 sellers, and 3 unchanged among 25 total holders.
• The aggregate institutional position in Pasithea Therapeutics amounted to 12.89Mn shares as of December 2025, up by 12.4Mn shares quarter on quarter, and up 12.81Mn shares year over year.
• Janus Henderson Group Plc leads ownership in KTTA with 2.1Mn shares as of December 31, 2025, equal to 28.21% of outstanding shares.
• Top purchasers of KTTA stock for the quarter ending December 2025 included Janus Henderson Group Plc (2.1Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.1Mn), Squadron Capital Management LLC (2.1Mn), Vivo Capital, LLC (2.1Mn), Ameriprise Financial Inc (1.93Mn).
• The largest sellers of Pasithea Therapeutics for the quarter ending December 2025 were CITADEL ADVISORS LLC (11.16K), UBS Group AG (5.12K), Jpmorgan Chase & Co (150), Bank Of America Corp /De/ (53).
• Business Quant data shows the 10 biggest positions in Pasithea Therapeutics as of December 2025 are held by Janus Henderson Group Plc (2.1Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.1Mn), Squadron Capital Management LLC (2.1Mn), Vivo Capital, LLC (2.1Mn), Ameriprise Financial Inc (1.93Mn), Cable Car Capital, LP (500.0K), ACUTA CAPITAL PARTNERS, LLC (450.0K), STEMPOINT CAPITAL LP (355.08K), AdvisorShares Investments LLC (304.72K), Persistent Asset Partners Ltd (290.56K).